Indivior welcomes results from buprenorphine-fentanyl interaction study
Indivior
932.00p
16:40 13/01/25
Pharmaceutical company Indivior hailed the results of a study aimed at assessing the ability of its buprenorphine asset to reduce respiratory depression and apnea associated with the synthetic opioid fentanyl.
FTSE 250
19,718.37
17:09 13/01/25
FTSE 350
4,509.22
17:10 13/01/25
FTSE All-Share
4,464.14
17:09 13/01/25
Pharmaceuticals & Biotechnology
20,419.76
17:10 13/01/25
Indivior said on Friday that the primary endpoint of the study was to determine the effects of escalating fentanyl dosing on respiratory depression as measured by minute ventilation with the maximum decrease in VE, induced by the highest dose of fentanyl, being almost 60% less with a steady-state plasma buprenorphine concentration of 2.0 ng/mL compared with placebo.
The FTSE 250-listed firm highlighted that the study showed the risk of experiencing apnea requiring verbal stimulation after fentanyl dosing was significantly lower with buprenorphine than with placebo.
Chief scientific officer Christian Heidbreder said: "The results of this proof-of-principle study increase our understanding of the role high sustained buprenorphine plasma concentrations may have in reducing fentanyl-induced respiratory depression.
"Future research is warranted to assess the competitive interaction of buprenorphine and fentanyl (as well as other illicitly manufactured fentanyl analogs) as we continue to deepen our understanding of buprenorphine as an evidence-based treatment for patients struggling with opioid use disorder."